Keloid
Drug research and approvals for keloid: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 19, 2026, 11 studies of keloid are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 11
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Keloid Pathogenesis And Fibroblast Activation StudyNCT07682636 · Not reported · The Fourth Affiliated Hospital of Zhejiang University School of Medicine · starts May 10, 2025
- Analyse of Diagnosis Value of Keloid on 68Ga-RGD PET-CTNCT07660406 · Phase 1 / Phase 2 · Peking Union Medical College Hospital · starts Aug 1, 2024
- Comparison Of Effectiveness Of Intralesional Injectioms Of 5 Flourouracil Alone Verses Its Cpmbination With Cryotherapy…NCT07531056 · Early Phase 1 · Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan · starts Dec 22, 2025
- Topical Cryotherapy and Keloid/Hypertrophic ScarsNCT07336368 · Phase 3 · Sonal Choudhary · starts Jun 10, 2026
- Measuring the Volumes of Hypertrophic Scars and Keloids, Two Specific Kind of Scars, Over Different Points in Time in…NCT06806735 · Not reported · University of Zurich · starts Jan 10, 2025
- Evaluation of Clinical, Perceived and Instrumental Efficacy of a Scar Gel in Preventing Hypertrophic ScarsNCT06751433 · Phase 1 / Phase 2 · Herbarium Laboratorio Botanico Ltda · starts Apr 3, 2025
- Intralesional Treatment of KeloidsNCT06729840 · Phase 3 · Sohag University · starts Dec 1, 2024
- Ritlecitinib in Patients With Keloids or Those Undergoing KeloidectomyNCT06373458 · Phase 2 · Icahn School of Medicine at Mount Sinai · starts Aug 13, 2024
- Radiotherapy for KeloidsNCT04722263 · Not applicable · Montefiore Medical Center · starts Dec 1, 2020
Phase 3 3
- TriamcinoloneGlucocorticoid receptor agonist
- Pirfenidone
- Fusidic acidElongation factor G inhibitor
Phase 2 8
- Triamcinolone acetonideGlucocorticoid receptor agonist
- ImiquimodToll-like receptor 7 agonist
- RitlecitinibTyrosine-protein kinase JAK3 inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- SorafenibSerine/threonine-protein kinase RAF inhibitor
- DupilumabInterleukin-4 receptor subunit alpha antagonist
- QAX-576Interleukin-13 inhibitor
- Remlarsen
Phase 1 or earlier 4
- Avotermin
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- LosartanType-1 angiotensin II receptor antagonist
- Insulin humanInsulin receptor agonist
How its trials ended
99 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 18 whose ending is known, 28% met their primary endpoint, 0% missed it and 72% stopped early.
- Completed, result not reported4747%
- Status unknown2222%
- Ongoing1212%
- Stopped: other or unclear66%
- Met its primary endpoint55%
- Stopped: enrollment or feasibility44%
- Stopped: lack of efficacy33%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA